Published in J Neuromuscul Dis on February 23, 2015
Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep (2015) 0.81
Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials. J Neuromuscul Dis (2016) 0.76
Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. Transl Psychiatry (2015) 0.76
A unifying genetic model for facioscapulohumeral muscular dystrophy. Science (2010) 4.87
Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet (2010) 2.95
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet (2012) 2.82
Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet (2003) 2.50
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain (2009) 2.38
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell (2011) 2.17
Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology (2006) 2.14
Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods (2008) 2.03
Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology (2010) 2.01
Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol (1999) 1.95
Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med (2011) 1.80
Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis. Thromb Haemost (2003) 1.65
Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve Suppl (1995) 1.43
171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2010) 1.40
Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet (2009) 1.35
Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve Suppl (1995) 1.23
Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord (2003) 1.19
Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord (2001) 1.19
Multiplexed microbead immunoassays by flow cytometry for molecular profiling: Basic concepts and proteomics applications. Crit Rev Biotechnol (2009) 1.18
CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol (2010) 1.16
Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. Proc Natl Acad Sci U S A (2012) 1.11
Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One (2012) 1.00
Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology (1999) 0.88
Insulin regulation of leptin synthesis and secretion in humans: the model of myotonic dystrophy. Clin Endocrinol (Oxf) (1999) 0.83
Clinical trial preparedness in facioscapulohumeral dystrophy: outcome measures and patient access: 8-9 April 2013, Leiden, The Netherlands. Neuromuscul Disord (2013) 0.83
Upregulation of chemokines and their receptors in Duchenne muscular dystrophy: potential for attenuation of myofiber necrosis. Muscle Nerve (2012) 0.82
Requirement of plasminogen binding to its cell-surface receptor α-enolase for efficient regeneration of normal and dystrophic skeletal muscle. PLoS One (2012) 0.80
Increased levels of tPA antigen and tPA/PAI-1 complex in myotonic dystrophy. J Intern Med (2001) 0.77
Immunohistochemical Characterization of Facioscapulohumeral Muscular Dystrophy Muscle Biopsies. J Neuromuscul Dis (2015) 0.75